List of Excipients in Branded Drug MOTRIN IB

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mechanical Servants LLC	MOTRIN IB	ibuprofen	29485-1465	CARNAUBA WAX
Mechanical Servants LLC	MOTRIN IB	ibuprofen	29485-1465	FD&C YELLOW NO. 6
Mechanical Servants LLC	MOTRIN IB	ibuprofen	29485-1465	FERRIC OXIDE RED
Mechanical Servants LLC	MOTRIN IB	ibuprofen	29485-1465	HYPROMELLOSE
Mechanical Servants LLC	MOTRIN IB	ibuprofen	29485-1465	MAGNESIUM STEARATE

Generic Drugs Containing MOTRIN IB

Company	Ingredient	NDC	Excipient
JC World Bell Wholesale Co Inc	ibuprofen	50269-000	ALUMINUM OXIDE
JC World Bell Wholesale Co Inc	ibuprofen	50269-000	CELLULOSE, MICROCRYSTALLINE
JC World Bell Wholesale Co Inc	ibuprofen	50269-000	CROSCARMELLOSE SODIUM
JC World Bell Wholesale Co Inc	ibuprofen	50269-000	FD&C RED NO. 40
JC World Bell Wholesale Co Inc	ibuprofen	50269-000	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in MOTRIN IB?

# Of NDCs	Excipient
5	ALUMINUM OXIDE
6	CELLULOSE, MICROCRYSTALLINE
6	CROSCARMELLOSE SODIUM
6	FD&C RED NO. 40
6	FD&C YELLOW NO. 6

Motrin IB Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

Motrin IB is an over-the-counter ibuprofen product positioned around a familiar 200 mg dose, rapid symptom relief, broad retail distribution, and low consumer acquisition cost. Its commercial protection depends more on brand equity, regulatory compliance, formulation performance, packaging, and retailer access than on pharmaceutical patent exclusivity. The largest excipient opportunities are in tablet robustness, faster disintegration, swallowability, coating performance, supply-chain resilience, and differentiated dosage forms.

Motrin IB is marketed in the United States by Kenvue Inc. following Johnson & Johnson’s consumer-health separation. The active ingredient is ibuprofen, a nonsteroidal anti-inflammatory drug indicated for temporary relief of minor aches and pains and reduction of fever. The standard product contains 200 mg of ibuprofen per tablet and is regulated under the FDA’s OTC internal analgesic monograph framework rather than through a prescription NDA-based market structure. [1-3]

What is Motrin IB and how is it regulated?

Motrin IB is an OTC immediate-release oral ibuprofen product.

Product attribute	Motrin IB position
Active ingredient	Ibuprofen
Strength	200 mg per tablet
Dosage form	Film-coated oral tablet or caplet, depending on SKU
Therapeutic class	OTC internal analgesic and antipyretic
U.S. regulatory pathway	OTC monograph framework
Primary commercial owner	Kenvue Inc.
Historic corporate association	Johnson & Johnson Consumer Health
Main competitive set	Advil, generic ibuprofen, store-brand ibuprofen, liquid gels, chewables
Core consumer use	Headache, minor muscular aches, toothache, backache, menstrual cramps, arthritis pain, and fever

The relevant FDA framework is the final monograph for internal analgesic, antipyretic, and antirheumatic drug products. Ibuprofen is permitted at specified OTC dosages and labeling conditions. The standard adult dose is typically 200 mg to 400 mg every four to six hours, subject to the product label and daily-use limitations. [1,2]

Because Motrin IB is an OTC monograph product, its commercial position does not depend on a conventional prescription-drug exclusivity period. Generic manufacturers can market equivalent ibuprofen products if they comply with the applicable monograph, labeling, manufacturing, and quality requirements.

What excipients are used in Motrin IB tablets?

Public product labeling identifies a conventional immediate-release tablet platform using fillers, binders, disintegrants, lubricants, coating agents, and processing aids.

Reported inactive ingredients for Motrin IB tablet presentations include:

• Corn starch
• Croscarmellose sodium
• Hypromellose
• Lactose monohydrate
• Magnesium stearate
• Microcrystalline cellulose
• Povidone
• Sodium lauryl sulfate
• Sodium starch glycolate
• Talc
• Titanium dioxide
• Colloidal silicon dioxide in certain listed presentations
• Film-coating and polishing materials, including carnauba wax in certain presentations

The exact excipient declaration can vary by product configuration, manufacturing site, tablet size, and package presentation. The FDA Drug Facts label and the manufacturer’s current package insert control for a specific SKU. [3]

Functional role of the principal excipients

Excipient category	Typical Motrin IB function	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and manufacturing throughput
Lactose monohydrate	Filler and compression aid	Low-cost bulk contribution; may create positioning limits for lactose-sensitive consumers
Corn starch	Diluent and disintegrant	Helps tablet breakup and cost control
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet disintegration
Sodium starch glycolate	Superdisintegrant	Increases swelling and aqueous breakup
Povidone	Binder	Improves granule and tablet integrity
Magnesium stearate	Lubricant	Reduces ejection force and tooling friction
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow and blend uniformity
Sodium lauryl sulfate	Wetting and dissolution aid	Can improve wetting of poorly water-soluble ibuprofen
Hypromellose	Film former	Protects the tablet and improves appearance and handling
Talc	Coating and anti-tacking aid	Supports coating performance
Titanium dioxide	Opacifier and colorant	Provides visual uniformity and light protection
Carnauba wax	Polishing agent	Improves surface finish and consumer appearance

Ibuprofen has limited aqueous solubility. Wetting agents, particle-size control, granulation conditions, and disintegrant selection therefore have a direct effect on dissolution behavior. A formulation that disintegrates quickly does not automatically produce faster clinical relief, but it can improve in vitro release and support a rapid-onset product claim when supported by the required evidence.

How strong is the Motrin IB formulation and brand protection?

Motrin IB has limited protection from traditional drug patents because ibuprofen is an established generic active ingredient. Its competitive protection is primarily based on:

1. Trademark recognition.
2. Retail distribution.
3. Consumer trust.
4. Packaging and shelf placement.
5. Product-line breadth.
6. Formulation execution.
7. Advertising and healthcare-provider familiarity.
8. Compliance with OTC labeling and quality requirements.

The Motrin name is a trademark asset rather than a pharmaceutical exclusivity right. Generic ibuprofen products can use the active ingredient name but cannot use Motrin branding or confusingly similar trade dress.

What patents protect Motrin IB?

No patent-based exclusivity period comparable to a newly approved prescription drug is central to the standard Motrin IB business model. The product’s active ingredient, ibuprofen, is long established, and multiple manufacturers sell OTC ibuprofen products.

Potential IP around a specific product may involve:

• Tablet manufacturing processes
• Coating systems
• Modified-release dosage forms
• Liquid-gel delivery systems
• Pediatric formulations
• Taste-masking technology
• Packaging systems
• Trade dress and trademarks

These rights would need to be evaluated by product SKU, jurisdiction, owner, prosecution history, and current legal status. They do not prevent ordinary monograph-compliant 200 mg ibuprofen tablets from entering the market.

When does Motrin IB lose exclusivity?

Motrin IB does not have a single patent expiration date that determines generic entry. Generic entry has already occurred through multiple OTC ibuprofen products.

The relevant commercial distinction is:

Protection type	Status for standard Motrin IB
Active-ingredient patent	Expired or commercially irrelevant
Prescription NDA exclusivity	Not the primary regulatory model
OTC monograph access	Available to compliant manufacturers
Trademark protection	Continues while maintained and used
Trade dress protection	Potentially available, subject to scope and enforcement
Product-specific formulation patents	SKU- and jurisdiction-dependent
Retail and brand protection	Ongoing but commercially contestable

A Paragraph IV challenge is generally not the normal route for a conventional OTC monograph ibuprofen tablet. Paragraph IV litigation is associated with an abbreviated new drug application challenging listed patents for an approved prescription or certain other NDA products. A manufacturer seeking to sell a monograph-compliant OTC ibuprofen tablet normally does not need to challenge a Motrin IB patent in the same manner as a generic prescription product challenging Orange Book-listed patents.

What is the Orange Book status of Motrin IB?

The standard Motrin IB OTC product should not be treated as an Orange Book-protected prescription product. The FDA Orange Book primarily identifies approved drug products, therapeutic equivalence information, patent listings, and exclusivity data for applicable NDA and ANDA products. OTC monograph products do not generally provide the same Orange Book patent barrier associated with prescription NDA products. [4]

Commercial diligence should distinguish among:

• Motrin IB OTC monograph tablets.
• Prescription ibuprofen products historically approved under an NDA.
• Ibuprofen products marketed under ANDAs.
• Other Motrin-branded dosage forms.
• Combination products that may have different regulatory histories.

The regulatory pathway, not the Motrin brand name alone, determines the relevance of Orange Book listings and Paragraph IV procedures.

What excipient strategy offers the strongest commercial opportunities?

The most attractive opportunity is not to duplicate the existing inactive-ingredient list. It is to improve a specific consumer or manufacturing outcome while remaining within the OTC regulatory framework.

1. Faster wetting and disintegration

Ibuprofen’s low water solubility creates an opportunity to optimize:

• Sodium lauryl sulfate concentration
• Superdisintegrant selection
• Disintegrant placement between intra- and extra-granular phases
• Particle-size distribution
• Granulation endpoint
• Tablet porosity
• Compression force
• Lubrication time

A supplier could commercialize a co-processed excipient system that combines a compressible filler with a superdisintegrant and flow aid. The value proposition would be lower formulation complexity, more consistent dissolution, and reduced sensitivity to compression-force changes.

2. Direct-compression platform

Direct compression can reduce processing steps, solvent use, drying requirements, and manufacturing cycle time. The principal technical barrier is achieving adequate flow, blend uniformity, tablet strength, and rapid disintegration at commercial scale.

A useful platform would combine:

• High-functionality microcrystalline cellulose
• Spray-dried lactose or a lactose-free substitute
• Co-processed starch or superdisintegrant
• Low-level colloidal silicon dioxide
• Controlled lubricant loading

The commercial target is a robust tablet that can run on high-speed presses without capping, lamination, sticking, or excessive ejection force.

3. Lactose-free and allergen-conscious positioning

The reported use of lactose monohydrate creates an opportunity for lactose-free reformulation. Potential alternatives include:

• Mannitol
• Sorbitol
• Dicalcium phosphate
• Compressible sucrose
• Crospovidone-containing co-processed systems
• Newer high-functionality cellulose excipients

A lactose-free formulation could support retailer-specific or premium OTC positioning. The market opportunity is limited if the product remains an undifferentiated 200 mg tablet, but it becomes more credible when combined with improved swallowability, cleaner labeling, or a defined sensitive-consumer target.

4. Swallowability and tablet-size reduction

Consumer adherence can be affected by tablet size, coating friction, shape, and hardness. Excipient strategies include:

• Higher-density fillers
• Improved compactability
• Tablet-shape optimization
• Low-friction film coatings
• Reduced coating weight
• Multi-particulate or mini-tablet formats

A smaller 200 mg tablet could reduce swallowing resistance, but dose loading, mechanical strength, dissolution, and packaging efficiency must remain acceptable. A smaller tablet is commercially useful only if it produces a measurable consumer benefit.

5. Chewable and orally disintegrating products

Chewable ibuprofen products create opportunities for pediatric and adult consumers who have difficulty swallowing tablets. The formulation challenges are substantial:

• Ibuprofen bitterness
• Mouthfeel
• Dose uniformity
• Moisture sensitivity
• Mechanical friability
• Sugar content
• Dental positioning
• Age-appropriate labeling

Taste-masking systems may use polymer coatings, ion-exchange resins, lipid barriers, flavor systems, or multiparticulate technology. These products can command higher pricing than commodity tablets, but they also face greater formulation and regulatory complexity.

6. Liquid and suspension systems

Ibuprofen suspension products require control of:

• Sedimentation
• Redispersibility
• Viscosity
• Particle growth
• pH
• Preservative performance
• Dose-device accuracy
• Flavor masking

Potential excipient systems include suspending polymers, wetting agents, buffering agents, sweeteners, flavors, and antimicrobial preservatives. The strongest opportunity is a stable, low-sugar or sugar-free product with accurate dosing and improved taste.

7. Gel-cap and lipid-based delivery

Liquid-filled capsules can improve swallowability and consumer perception of rapid action. Lipid vehicles, surfactants, and cosolvents may improve wetting and dispersion, but they raise manufacturing, capsule-shell, leakage, stability, and scale-up considerations.

A gel-cap strategy is more commercially differentiated than another compressed tablet. It is also more exposed to manufacturing cost, capsule supply, packaging compatibility, and patent or trade-secret barriers around the delivery system.

Which companies are challenging Motrin IB commercially?

The main competitive pressure comes from generic and store-brand ibuprofen products rather than from patent challengers.

Competitor type	Examples	Competitive advantage
Branded OTC	Advil and related products	Strong brand recognition and advertising
Retail private label	CVS, Walgreens, Walmart, Target and other store brands	Lower price and high shelf access
Generic manufacturers	Multiple FDA-compliant suppliers	Low manufacturing and marketing cost
Alternative dosage forms	Liquid gels, chewables, suspensions	Convenience and differentiation
Combination products	Ibuprofen with other actives in permitted products	Symptom-specific positioning
E-commerce brands	Direct-to-consumer OTC sellers	Lower overhead and targeted marketing

Advil is the closest national branded comparator. Store brands usually compete on price, while Motrin IB competes on brand familiarity, pain-relief recognition, and distribution. The largest commercial risk is private-label substitution at the shelf, not a Paragraph IV lawsuit.

What formulation patents and manufacturing barriers matter?

Formulation patents may be relevant where a product uses a nonstandard dosage form or delivery platform. The most defensible areas include:

• Rapid-release ibuprofen compositions
• Taste-masked particles
• Liquid-filled capsules
• Pediatric suspensions
• Abuse-resistant or tamper-evident packaging
• Specific coating compositions
• Manufacturing processes that improve content uniformity
• Stabilized combinations with other active ingredients

Manufacturing barriers can be more important than patent barriers. These include:

• Reliable supply of pharmaceutical-grade ibuprofen
• Control of powder flow and segregation
• Tablet sticking and picking
• Coating uniformity
• Dissolution reproducibility
• Moisture control
• High-speed compression performance
• Stability across temperature and humidity
• Packaging compatibility
• Low-cost, compliant production at scale

For a commodity OTC tablet, the formulation must be inexpensive enough to compete with private label. A technically superior formulation that raises unit cost without a clear consumer benefit is unlikely to create durable share.

How does Motrin IB compare with Advil?

Motrin IB and Advil both rely on ibuprofen as the active ingredient and compete within the same OTC pain-relief category.

Factor	Motrin IB	Advil
Active ingredient	Ibuprofen	Ibuprofen
Standard strength	200 mg	200 mg
Regulatory category	OTC monograph	OTC monograph
Core protection	Brand and distribution	Brand and distribution
Generic substitution risk	High	High
Excipient differentiation	SKU-specific	SKU-specific
Main opportunity	Swallowability, rapid release, value extensions	Similar formulation and dosage-form extensions
Patent dependence	Low for standard tablet	Low for standard tablet

The key competitive question is not whether one brand has a stronger ibuprofen molecule. Both use the same active ingredient. The relevant variables are product experience, price, package architecture, retailer relationships, advertising, and dosage-form innovation.

What is the FDA regulatory status and commercial pathway?

A new conventional ibuprofen tablet can generally be developed under the applicable OTC monograph if it meets the monograph’s active-ingredient, dosage, labeling, quality, and manufacturing requirements. A formulation with a novel indication, nonmonograph active ingredient, materially different dosage form, or unsupported claim may require a different FDA pathway.

Commercial pathways include:

1. Private-label supply to national retailers.
2. Contract manufacturing for regional brands.
3. Premium branded products with differentiated excipients.
4. Pediatric and family-care extensions.
5. Chewable or orally disintegrating formats.
6. Gel-cap or liquid-filled capsule formats.
7. Lactose-free or sugar-free products.
8. Sustainable packaging and lower-material formats.
9. International OTC registrations.

The excipient change-control burden depends on the scale of the change. A minor inactive-ingredient adjustment still requires quality, stability, dissolution, manufacturing, and labeling review. A new dosage form can require a broader development package, including safety and performance support.

What geographic markets offer opportunity?

The United States is highly competitive and price-sensitive. Growth opportunities are more likely to arise from dosage-form differentiation and private-label partnerships than from another standard tablet.

Potential geographic strategies include:

• North America: private label, club stores, and value packs.
• Europe: national OTC registration and country-specific labeling.
• Latin America: branded generics and family-care products.
• Asia-Pacific: pediatric liquids, smaller pack sizes, and e-commerce.
• Middle East and Africa: heat-stable formulations and robust packaging.

Excipient suppliers should prioritize systems that remain stable under humidity and temperature stress. Packaging and stability performance can be decisive in markets with long distribution chains.

What revenue exposure does Motrin IB create for suppliers?

Kenvue does not generally disclose product-level Motrin IB revenue in a way that isolates excipient purchasing. Supplier exposure is therefore best assessed through product volume, manufacturing footprint, and the number of SKUs using the formulation rather than through a published brand-specific revenue figure.

The largest recurring supplier opportunities are:

• High-volume cellulose and starch excipients
• Superdisintegrants
• Film-coating systems
• Lubricants and glidants
• Taste-masking polymers
• Suspension stabilizers
• Capsule-shell materials
• Moisture-barrier packaging
• Co-processed direct-compression excipients

Commodity excipients face price pressure. Specialty excipients can support higher margins when they improve dissolution, reduce manufacturing failures, enable a smaller tablet, or support a differentiated regulatory claim.

What generic launch risks exist for Motrin IB?

Generic launch risk is structurally high for standard 200 mg ibuprofen tablets because:

• The active ingredient is widely available.
• OTC monograph access reduces regulatory barriers.
• Many manufacturers have established tablet platforms.
• Private-label retailers can switch suppliers.
• Consumer substitution is easy.
• Price comparison is straightforward.

Brand resilience is stronger in:

• Liquid gels
• Pediatric products
• Combination products
• Large family packs
• Travel formats
• Retailer-exclusive packaging
• Products with clear swallowability or onset advantages

The most credible defense is a differentiated consumer proposition supported by reliable formulation performance and distribution, not an attempt to create exclusivity around ordinary ibuprofen tablets.

Key Takeaways

• Motrin IB is a 200 mg OTC ibuprofen product marketed primarily through brand, distribution, and consumer recognition.
• Its standard tablet business is not dependent on a conventional patent or prescription exclusivity period.
• The main competitive threat is generic and private-label substitution.
• Core excipient functions include compression, disintegration, wetting, lubrication, coating, and tablet protection.
• The strongest formulation opportunities are rapid disintegration, smaller tablets, lactose-free systems, chewables, pediatric liquids, and gel-cap delivery.
• Co-processed excipient platforms can reduce manufacturing complexity and improve high-speed tableting.
• Excipient suppliers should target measurable performance improvements rather than simple ingredient substitution.
• Product-level Motrin IB revenue and SKU-specific patent positions are not generally disclosed in public regulatory labeling.
• Manufacturing reliability, cost, stability, and retailer access are more important than patent barriers for standard ibuprofen tablets.

FAQs

Can a new company launch a competing ibuprofen tablet without a Motrin license?

Yes. A company can market a compliant OTC ibuprofen product without licensing the Motrin trademark, provided it meets FDA requirements and avoids infringing third-party rights.

Does lactose in Motrin IB create a regulatory safety issue?

Lactose is an inactive ingredient used in many oral tablets. Its presence is primarily a formulation and labeling consideration, not a basis for therapeutic exclusivity.

Which excipient can most improve ibuprofen dissolution?

A combined strategy using particle-size control, effective wetting, appropriate superdisintegrants, and controlled compression is generally more important than selecting one excipient in isolation.

Is an orally disintegrating ibuprofen tablet commercially attractive?

It can be attractive for consumers who have difficulty swallowing tablets, but bitterness, dose loading, mechanical strength, packaging, and moisture control make development more complex than a standard tablet.

Can sustainable excipients create a premium Motrin-like product?

Potentially, but the commercial case requires a measurable benefit such as reduced manufacturing energy, improved supply security, lower packaging impact, or a credible consumer-facing label claim.

References

1. U.S. Food and Drug Administration. (2020). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.

2. U.S. Food and Drug Administration. (2022). Over-the-counter monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. FDA.

3. Kenvue Inc. (n.d.). Motrin IB ibuprofen tablets, 200 mg: Drug facts and inactive ingredients. Product labeling.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.